Does maximizing programmed cell death necessarily yield an optimum clinical advantage?
Generally it has been believed that a maximum therapeutic induction of programmed cell death in cancer cells is universally desirable. As a corollary, the presence of Bcl-2, a major anti-programmed cell death protein, is considered an unfavorable prognostic sign. The latter is not and the former may not be universally true.
Ou
D
D
Department of Pathology, University of Illinois Medical School at Chicago and the West Side V.A. Hospital, USA.
Anderson
K M
KM
Leslie
W
W
Bonomi
P
P
Harris
J E
JE
D000818:Animals; D017209:Apoptosis; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis / Q000502:physiology
D019253:Proto-Oncogene Proteins c-bcl-2